Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network
Ross D. Williams,Aniek F. Markus,Cynthia Yang,Talita Duarte Salles,Thomas Falconer,Jitendra Jonnagaddala,Chungsoo Kim,Yeunsook Rho,Andrew Williams,Min Ho An,María Aragón,Carlos Areia,Edward Burn,Young Choi,Iannis Drakos,Maria Fernandes Abrahão,Sergio Fernández-Bertolín,George Hripcsak,Benjamin Kaas-Hansen,Prasanna Kandukuri,Jan A. Kors,Kristin Kostka,Siaw-Teng Liaw,Gerardo Machnicki,Daniel Morales,Fredrik Nyberg,Rae Woong Park,Albert Prats-Uribe,Nicole Pratt,Gowtham Rao,Christian G. Reich,Marcela Rivera,Tom Seinen,Azza Shoaibi,Matthew E. Spotnitz,Ewout W. Steyerberg,Marc A Suchard,Seng Chan You,Lin Zhang,Lili Zhou,Patrick B. Ryan,Daniel Prieto-Alhambra,Jenna M. Reps,Peter R. Rijnbeek
DOI: https://doi.org/10.1101/2020.05.26.20112649
2020-01-01
MedRxiv
Abstract:Importance COVID-19 is causing high mortality worldwide. Developing models to quantify the risk of poor outcomes in infected patients could help develop strategies to shield the most vulnerable during de-confinement. Objective To develop and externally validate COVID-19 Estimated Risk (COVER) scores that quantify a patient's risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis. Design Multinational, distributed network cohorts. Setting We analyzed a federated network of electronic medical records and administrative claims data from 13 data sources and 6 countries, mapped to a common data model. Participants Model development used a patient population consisting of >2 million patients with a general practice (GP), emergency room (ER), or outpatient (OP) visit with diagnosed influenza or flu-like symptoms any time prior to 2020. The model was validated on patients with a GP, ER, or OP visit in 2020 with a confirmed or suspected COVID-19 diagnosis across four databases from South Korea, Spain and the United States. Outcomes Age, sex, historical conditions, and drug use prior to index date were considered as candidate predictors. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death, and iii) death in the 30 days after index date. Results Overall, 43,061 COVID-19 patients were included for model validation, after initial model development and validation using 6,869,127 patients with influenza or flu-like symptoms. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, and kidney disease) which combined with age and sex could discriminate which patients would experience any of our three outcomes. The models achieved high performance in influenza. When transported to COVID-19 cohorts, the AUC ranges were, COVER-H: 0.73-0.81, COVER-I: 0.73-0.91, and COVER-F: 0.82-0.90. Calibration was overall acceptable, with overestimated risk in the most elderly and highest risk strata. Conclusions and relevance A 9-predictor model performs well for COVID-19 patients for predicting hospitalization, intensive services and death. The models could aid in providing reassurance for low risk patients and shield high risk patients from COVID-19 during de-confinement to reduce the virus' impact on morbidity and mortality.